As a new-type foreign trade service provider driven by both technology commercialization and foreign trade, HiSiaddi has established a service system summarized as “1+2+3+4=1” and can supply dibenzyl ether sourced from multiple well-known original manufacturers. Possessing R&D capabilities, HiSiaddi frequently proposes dibenzyl ether formula optimization plans and application improvement suggestions through technological cooperation with manufacturers and precise market insight. Below is a consulting case regarding dibenzyl ether formula optimization by HiSiaddi.
Contact HiSiaddi customer service for more formula optimization consulting services.
This case builds on the customized cooperation outlined in Case 1. The client is BIOPHARMA AG of Switzerland, a listed European pharmaceutical enterprise focusing on targeted innovative drugs and high-end cephalosporin API R&D. Its entire production line adheres to the European Pharmacopoeia (EP), ICH Q3 impurity control standards, GMP aseptic production and top-tier EDMF drug filing requirements, with end products supplied to the EU prescription drug system. It imposes zero-defect standards on trace impurity controllability, reaction compatibility, batch consistency and absence of side reaction interference for raw materials.
The client purchases 120 tons of HiSiaddi customized ≥99.85% high-purity pharmaceutical-grade dibenzyl ether annually, which serves as a key inert solvent for hydroxyl protection in multi-step new drug synthesis and directly determines API purity and yield. The first customized 60-ton batch of high-purity dibenzyl ether passed 100% of full physical and chemical indicator testing upon arrival (purity, moisture, color, benzyl alcohol, benzyl chloride and peroxides all met contracted pharmacopoeia standards), fully matching original imported LANXESS material. However, after mass production trials using the domestic customized material, four severe mass production abnormalities emerged consecutively: reduced synthetic reaction selectivity, residual impurities after hydrogenation deprotection, decreased monomer purity of APIs and volatile batch yields.
The client’s internal pharmaceutical R&D, synthetic process and quality compliance teams spent 30 days repeatedly adjusting reaction temperature, feed molar ratio, hydrogenation pressure, catalyst dosage and reaction duration, yet failed to eliminate process abnormalities. The batch qualification rate of APIs plummeted from a stable 99.4% with imported materials to 92.1%, with multiple batches of intermediates unable to proceed to subsequent processes due to excess impurities, severely delaying new drug mass production delivery. The client determined that subtle differences in microphysical properties and trace latent components between the domestic customized raw material and original European imported material caused compatibility failure in the high-end pharmaceutical synthesis system—a sophisticated fine chemical technical issue undetectable by routine testing and unsolvable by ordinary traders. HiSiaddi’s technical team was urgently invited to conduct on-site special traceability diagnosis and comprehensive formula & process optimization.
None of these issues stemmed from non-compliant raw material indicators; rather, subtle differences in trace latent components, polarity distribution, thermal stability and storage characteristics between domestic high-purity dibenzyl ether and European imported material led to incompatibility with the client’s mature formula processes tailored for imported raw materials. This represents a typical compatibility challenge during substitution of high-end pharmaceutical raw materials.
While peroxide levels in domestic refined dibenzyl ether met the contracted standard of <5ppm, there remained a trace gap compared to imported LANXESS material with <2ppm baseline peroxides. Under the client’s long-duration high-temperature reflux synthesis conditions, trace peroxides continuously induced mild oxidative side reactions generating trace benzene derivative impurities, directly lowering intermediate API purity and failing to satisfy the strict ICH single impurity limit of <0.05%.
Imported dibenzyl ether features an extremely narrow rectification cut range and highly uniform polarity distribution. Although domestic high-purity material meets the main content standard, slight variations in the distribution of trace wide-boiling polar components reduce the selectivity of the client’s hydroxyl protection reactions, leaving partial hydroxyl groups unprotected and triggering disordered side reactions in subsequent addition reactions that drag down final product yields.
The client adopts catalytic hydrogenation debenzylation in downstream processes; imported materials feature an extremely inert system with no interference. Trace residual unsaturated minor components in domestic material slightly adsorb active sites on catalysts, causing incomplete localized hydrogenation reactions and detectable deprotection residues in final APIs that fail European Pharmacopoeia release testing.
Dibenzyl ether exhibits weak oxygen absorption and oxidation tendencies. Domestic refined material demonstrates inferior anti-oxidation stability relative to imported material. The client’s original open sampling and conventional sealed storage processes, designed for highly stable imported raw materials, result in gradual oxygen uptake and rising peroxide levels after opening domestic material batches, triggering sharp fluctuations in API yields and inconsistent product quality across batches.
HiSiaddi dispatched a dedicated technical team consisting of fine ether synthesis engineers, pharmaceutical synthesis process specialists and pharmacopoeia impurity analysts. Through full-component GC chromatogram benchmarking between imported and domestic materials, review of physical property discrepancies, traceability of impurities from failed intermediates and replication verification of process parameters, four core root causes were identified:
1. While domestic rectification processes achieve compliance with main content standards, the distribution of trace polar impurity components and trace unsaturated impurities differs from imported material, interfering with high-precision pharmaceutical synthesis reactions;
2. The baseline peroxide level of domestic material exceeds that of top-tier imported raw materials, and side reactions are amplified under prolonged high-temperature reaction conditions;
3. The client’s original formula, catalytic system and hydrogenation parameters were finalized based on the inert characteristics of imported materials with no compatibility redundancy for domestic alternatives;
4. The client’s raw material storage, sampling and feeding procedures lack inert gas protection, exacerbating the oxidative susceptibility defect of domestic material.
Strictly adhering to the principle of avoiding alterations to the client’s core pharmaceutical synthesis main process and core formula ratios, HiSiaddi delivered minimal-invasive rectifications across four dimensions: post-production refining upgrades for raw materials, micro-adjustment of formula additives, adaptation of synthetic process parameters and standardization of warehouse & feeding workflows, perfectly aligning domestic dibenzyl ether physical properties with the client’s system.
Collaborating with the manufacturing plant, HiSiaddi added an inert nitrogen atmosphere deep de-peroxidation and molecular sieve polar impurity adsorption refining unit to the original customized process:
1. A low-temperature negative-pressure inert devolatilization step was added post-finishing to further reduce baseline peroxides to ≤2ppm, matching top-tier imported material levels;
2. Special polar adsorption filler filtration was introduced to precisely remove trace polar impurity components, aligning raw material polarity distribution and inertness fully with imported alternatives;
3. A revised refined product SOP was formalized and enforced for all subsequent mass production batches, eliminating root triggers of side reactions from the source.
In response to the differential oxidative susceptibility of domestic raw materials, trace pharmaceutical-grade dedicated anti-oxidation stabilizers (non-reactive in pharmaceutical synthesis, residue-free and EP Pharmacopoeia compliant) were added to the client’s original synthesis system. Six sets of gradient lab trials identified the optimal addition ratio, completely eliminating oxidative side reactions under high-temperature reflux conditions and removing the source of unknown impurity generation.
Combined with the trace component characteristics of domestic raw materials, hydrogenation pressure, catalyst dosage and constant-temperature holding duration were fine-tuned, and catalyst dispersion uniformity optimized to compensate for reaction gaps arising from raw material inertness differences, achieving complete benzyl group removal with zero residues and no by-products—matching deprotection performance of imported materials.
1. Establish exclusive pharmaceutical-grade dibenzyl ether warehouse standards: constant temperature, light-shielded storage with stable humidity ≤40%;
2. Implement full nitrogen inert protection during raw material opening, sampling, sub-packaging and feeding to eliminate oxygen absorption and oxidation;
3. Immediately seal unused raw materials under nitrogen to avoid physical property fluctuations between batches.
Assist the client in establishing a pre-production lab trial verification mechanism for every raw material batch: small-scale synthesis and impurity chromatogram comparison are conducted for each bulk shipment prior to full-scale production to predict compatibility in advance and prevent mass production abnormalities.
HiSiaddi issued English GMP-level standardized operation guidelines covering raw material acceptance, storage, pre-treatment, feeding, reaction parameter control and abnormality troubleshooting, delivering full special training to the client’s R&D, production and QA quality teams to enable independent stable mass production by the client.
Ten consecutive full-load mass production batches were validated post-solution implementation, with all quantified outcomes achieved:
1. Complete elimination of side reactions: Unknown and single impurities in APIs were fully controlled within ICH limits, fully complying with EP Pharmacopoeia release standards;
2. Fully compliant deprotection process: Debenzylation residue issues were completely resolved, with intermediate purity restored to imported material standards;
3. Sharp rise in mass production yield: API batch qualification rate rebounded from 92.1% to 99.5%, exceeding the stability of original imported material mass production;
4. Uniform batch consistency: Batch fluctuation issues were fully resolved, with highly unified indicators across multiple production batches;
5. Significant cost optimization: Combined with domestic raw material supply and process optimization, the client’s comprehensive production cost for this raw material category dropped by 18.7%, drastically reducing losses from scrapped intermediates.
1. The client fully eliminated concerns regarding compatibility of high-end domestic pharmaceutical raw materials, with stable annual performance of the 120-ton dibenzyl ether customized framework contract;
2. HiSiaddi was designated as a pre-R&D raw material compatibility certification partner for the client’s pipeline new drugs, with all localization substitution validation for special solvents required by its pipeline new drugs completed in advance by HiSiaddi;
3. Multiple subsequent high-end ether and alcohol pharmaceutical solvent product lines of the client were exclusively entrusted to HiSiaddi for customized manufacturing and supporting technical services.
1. For high-end pharmaceutical raw materials, meeting indicator standards does not guarantee process compatibility: compliance with pharmacopoeia physical and chemical data represents only a basic threshold. Subtle latent component differences, polarity distribution and oxidative stability discrepancies constitute invisible root causes of synthetic side reactions, excess impurities and reduced yields in high-end pharmaceutical synthesis—technical blind spots entirely unidentifiable and unsolvable by ordinary manufacturers and low-end traders.
2. Core Differentiated Value of HiSiaddi: Beyond product supply, HiSiaddi possesses comprehensive high-end technical capabilities including raw material synthesis mechanism expertise, pharmaceutical synthesis process compatibility analysis, impurity traceability diagnosis and mass production process optimization, bridging compatibility gaps between raw material manufacturers and end pharmaceutical synthesis workflows.
3. Core Rigorous Demand of European and American High-End Pharmaceutical Enterprises: Stable, traceable, side-reaction-free and high-end synthesis process-matching technical supporting services carry far greater weight than low-cost raw material supply, forming core barriers securing long-term high-end client partnerships.
Contact HiSiaddi customer service for more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
